A new mRNA cancer vaccine developed at the University of Florida shows promise in treating glioblastoma by triggering a rapid immune response. Tested in animals and a small group of patients, the vaccine employs personalized tumor cells and innovative nanoparticle technology. Upcoming trials will further explore its safety and efficacy in both adults and children.
Glioblastoma is among the most devastating diagnoses, with median survival of around 15 months. The current standard of care involves surgery, radiation, and some combination of chemotherapy. “The demonstration that making an mRNA cancer vaccine in this fashion generates similar and strong responses across mice, pet dogs that have developed cancer spontaneously and human patients with brain cancer is a really important finding, because oftentimes we don’t know how well the preclinical studies in animals are going to translate into similar responses in patients,” said Duane Mitchell, M.D., Ph.D.
The next step, through support from the Food and Drug Administration and the CureSearch for Children’s Cancer foundation, will be an expanded Phase I clinical trial to include up to 24 adult and pediatric patients to validate the findings. Once an optimal and safe dose is confirmed, an estimated 25 children would participate in Phase 2, said Sayour, an associate professor in the Lillian S.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: trtworld - 🏆 101. / 63 Read more »
Source: CBS8 - 🏆 335. / 59 Read more »
Source: SAReport - 🏆 252. / 63 Read more »
Source: axios - 🏆 302. / 63 Read more »
Source: clevelanddotcom - 🏆 301. / 63 Read more »